RZC — 7.125% Fixed-Rate Reset Subordinated Debentures due 2052

RZC Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Operating EPS: Reported at $6.37 per share, exceeding expectations.
• Pretax Adjusted Operating Income: $534 million for the quarter.
• Return on Equity: Adjusted operating return on equity at 14.2% for the trailing 12 months.
• Premium Growth: Traditional business premiums increased by 8.5% year-to-date on a constant currency basis.
• Capital Deployment: $2.4 billion deployed year-to-date, including $1.5 billion for the Equitable transaction and $900 million across 20 other transactions.
• Excess Capital: Estimated at $2.3 billion with deployable capital of $3.4 billion.

2. Strategic Updates and Business Highlights

• Equitable Transaction: Closed in Q3, contributing positively to earnings and expected to yield $70 million in pretax income for the full year, increasing to $200 million by 2027.
• Global Performance: Strong results in Asia Traditional, EMEA, and U.S. Financial Solutions, with a robust pipeline of new business opportunities.
• In-Force Management: Continued focus on in-force actions, contributing approximately $45 million year-to-date, with expectations of ongoing opportunities.
• Ruby Re: Progressing with retrocessions and expected to be fully deployed by mid-2026.
• Innovation: Successful introduction of new products in Asia, including a critical illness combination product in Mainland China and a second-generation cancer treatment product in Korea.

3. Forward Guidance and Outlook

• New Business Pipeline: Remains strong across all regions, with selective opportunities based on expected returns and strategic considerations.
• Long-Term Strategy: Confident in the ability to deliver on intermediate-term financial targets and return excess capital to shareholders through dividends and share repurchases.
• Value of In-Force Business Margins: Increased by 16% over the past three quarters, indicating strong long-term earnings potential.

4. Bad News, Challenges, or Points of Concern

• Claims Experience: U.S. Traditional segment faced modestly unfavorable claims experience, with a negative impact of $50 million in the quarter.
• Variable Investment Income: Lower than expected by approximately $40 million, primarily due to reduced real estate joint venture activity.
• Group Business: Expected to be breakeven for the second half of the year, with ongoing challenges in the medical segment leading to a need for repricing by January 2026.
• Market Competition: Concerns about becoming more aggressive in pricing to win business, although management asserts that risk appetite and strategy remain unchanged.

5. Notable Q&A Insights

• U.S. Claims Activity: Management indicated that the negative claims experience is largely normal volatility, with no significant one-time items affecting premiums.
• Mortality Assumptions: Adjustments in the U.K. reflect ongoing excess mortality, but the net economic effect is neutral due to a balanced book of business.
• LDTI Impact: Management remains confident in the long-term benefits of LDTI for smoothing results, despite short-term volatility.
• Ruby Re Liabilities: Focused on simple, asset-intensive liabilities, with plans to explore additional sidecars in the future.
• Economic Solvency in Japan: Seen as a driver of opportunity, with increased activity in coinsurance of blocks, leveraging long-standing client relationships.

Overall, RGA reported a strong quarter with record financial performance, strategic advancements, and a positive outlook, despite facing some challenges in claims experience and competitive pressures.